Objective To observe the clinical efficacy of sequential application of Feibi Decoction（ 肺痹汤） and Qianjin Weijing Decoction（ 千金苇茎汤） in adjuvant treatment of severe pulmonary thromboembolism. Methods A total of 114 patients with severe pulmonary thromboembolism were randomly divided into western medicine group of 56 cases and sequential group of 58 cases. The western medicine group was treated with conventional western medicine.The sequential group was given the sequential treatment of Feibi Decoction and Qianjin Weijing Decoction on the basis of conventional western medicine treatment

one dose per day with alternative use for 4 weeks. The scores of traditional Chinese medicine（ TCM） syndromes

respiratory rate

blood gas index

serological index and hospitalization time before and after treatment were compared

and the clinical efficacy and safety were evaluated. Results The two groups finally included 51 cases in each for statistics. After treatment

the TCM syndrome scores

respiratory rate

serum endothelin 1

tissue plasminogen activator and thromboxane B2 levels were lower than those before treatment

and the sequential group was lower than the western medicine group（ P < 0. 05）. After treatment

the arterial oxygen partial pressure and carbon dioxide partial pressure were higher than those before treatment

and the sequential group was higher than the western medicine group（ P < 0. 05）. The total effective rate was 98. 04% in the sequential group after treatment

which was higher than 84. 31% in the western medicine group（ P < 0. 05）. The incidence of adverse reactions in the sequential group was 3. 92%

and that in the western medicine group was 5. 88%. There was no statistical difference between the two groups（ P > 0. 05）. The hospitalization time of the sequential group and the western medicine group were（ 5. 6 ± 1. 2） weeks and（ 7. 4 ± 1. 3） weeks respectively

and the difference was statistically significant（ P < 0. 05）. Conclusion Sequential applicationt of Feibi Decoction and Qianjin Weijing Decoction in the treatment of patients with severe pulmonary thromboembolism can alleviate symptoms

improve respiratory rate and blood gas index

protect vascular endothelial function

reduce clotting factor activity

and significantly shorten hospitalization time.